Direct‐Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis

Camila C. Simoes, Omar A. Saldarriaga, Netanya S. Utay, Ashley E. Stueck, Sheharyar K. Merwat, Shehzad N. Merwat, Thomas D. Schiano, Maria Isabel Fiel, Heather L. Stevenson – 8 June 2019 – Patients with hepatitis C virus (HCV) often have elevated serum markers and histologic features of autoimmune hepatitis (AIH). We evaluated an HCV‐positive (HCV+) study group that had elevated serum markers of AIH before starting direct‐acting antiviral (DAA) therapy (n = 21) and compared them to an HCV+ control group that did not have laboratory studies suggesting AIH (n = 21).

Tumor‐Specific Transcripts Are Frequently Expressed in Hepatocellular Carcinoma With Clinical Implication and Potential Function

Qiupeng Zheng, Jingjing Zhao, Hui Yu, Huajie Zong, Xigan He, Yiming Zhao, Yan Li, Yu Wang, Yichao Bao, Yuchen Li, Bing Chen, Weijie Guo, Yilin Wang, Zhiao Chen, Yingjun Zhao, Lu Wang, Xianghuo He, Shenglin Huang – 7 June 2019 – Hepatocellular carcinoma (HCC) is a highly lethal cancer and its underlying etiology remains understudied. The immense diversity and complexity of the cancer transcriptome hold the potential to yield tumor‐specific transcripts (TSTs).

Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease

Pegah Golabi, Natsu Fukui, James Paik, Mehmet Sayiner, Alita Mishra, Zobair M. Younossi – 6 June 2019 – Cardiovascular diseases (CVDs) are the leading cause of mortality in patients with nonalcoholic fatty liver disease (NAFLD). Our aim was to assess the association of atherosclerotic cardiovascular disease (ASCVD) risk scores with overall and cardiac‐specific mortality among patients with NAFLD. We used the National Health and Nutrition Examination Survey III with the National Death Index‐linked mortality files.

Genetic Polymorphisms Implicated in Nonalcoholic Liver Disease or Selected Other Disorders Have No Influence on Drug‐Induced Liver Injury

Herbert L. Bonkovsky, Tyler Severson, Paola Nicoletti, Huiman Barnhart, Jose Serrano, Naga Chalasani, Robert J. Fontana, Paul B. Watkins, Victor Navarro, Andrew Stolz, Ann K. Daly, Guruparasad P. Aithal, Joseph Odin, the US DILIN Investigators – 6 June 2019 – With the application of genetic testing to contemporary medical diagnostics and practice, it has become apparent that the phenotypes of many disorders are modulated by host genetic factors.

Lipoprotein Lipase Up‐regulation in Hepatic Stellate Cells Exacerbates Liver Fibrosis in Nonalcoholic Steatohepatitis in Mice

Toshiaki Teratani, Kengo Tomita, Hirotaka Furuhashi, Nao Sugihara, Masaaki Higashiyama, Makoto Nishikawa, Rie Irie, Takeshi Takajo, Akinori Wada, Kazuki Horiuchi, Kenichi Inaba, Yoshinori Hanawa, Naoki Shibuya, Yoshikiyo Okada, Chie Kurihara, Shin Nishii, Akinori Mizoguchi, Hideaki Hozumi, Chikako Watanabe, Shunsuke Komoto, Shigeaki Nagao, Junji Yamamoto, Soichiro Miura, Ryota Hokari, Tananori Kanai – 6 June 2019 – Lipoprotein lipase (LPL) plays a central role in incorporating plasma lipids into tissues and regulates lipid metabolism and energy balance in the human body.

Childhood Socioeconomic Disadvantage and Risk of Fatty Liver in Adulthood: The Cardiovascular Risk in Young Finns Study

Tomi T. Laitinen, Jussi Vahtera, Katja Pahkala, Costan G. Magnussen, Joel Nuotio, Nina Hutri‐Kähönen, Mika Kivimäki, Terho Lehtimäki, Eero Jokinen, Tomi Laitinen, Päivi Tossavainen, Jaana Pentti, Jorma S.A. Viikari, Markus Juonala, Olli T. Raitakari – 6 June 2019 – Fatty liver is a preventable cause of liver failure, but early risk factors for adulthood fatty liver are poorly understood. We examined the association of childhood socioeconomic disadvantage with adulthood fatty liver and tested adulthood risk factors of fatty liver as possible mediators of this link.

Subscribe to